Neurology Alert – August 1, 2022

Noradrenergic Drugs for the Symptomatic Treatment of Alzheimer’s Disease

This meta-analysis provides evidence that drugs modulating the noradrenergic system could be effective in treating cognitive symptoms and apathy in patients with Alzheimer’s disease.

Risk Factors Associated with Alzheimer’s Disease and Related Dementias in the United States

Two independent analyses of U.S. national surveys support evidence that targeted risk-reduction strategies may reduce the burden of Alzheimer’s disease in the population.

Myopathy Is Associated with Post-COVID-19 Fatigue

Prolonged fatigue after COVID-19 infection may be associated with evidence of myopathy, based on physical examination, electromyography, and muscle biopsy.

COVID-19 and Headache

Headache is a common feature of acute COVID-19 infection, as well as a long-standing feature of “long COVID” after recovery from the acute infection. Treatment is symptomatic, based on the characteristics of the headache syndrome.